DJIA 16,214.99 156.64 0.98%
NASDAQ 4,688.31 52.21 1.13%
S&P 500 1,928.64 14.79 0.77%
market minute promo

Regeneron Pharmaceuticals (NASDAQ: REGN)

502.98 6.56 (1.32%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $502.98 1.32%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $503.71
Previous Close $496.42
Daily Range $493.75 - $506.20
52-Week Range $320.06 - $605.93
Market Cap $52.2B
P/E Ratio 125.36
Dividend (Yield) $0.00 (0.0%)
Volume 201,152
Average Daily Volume 815,111
Current FY EPS $9.61

Sector

Healthcare

Industry

Drug Makers

Regeneron Pharmaceuticals (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary Rss Feed

Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern

Repatha gets the green light from the Food and Drug Administration, but pharmacy benefit managers and insurers are ready to give PCSK9 inhibitors the red light.

4 Google-Beating Stocks that Still Hold Promise

The Zacks Analyst Blog Highlights: Amazon.com, Skyworks Solutions, Regeneron Pharmaceuticals and Uni

The Zacks Analyst Blog Highlights: Amazon.com, Skyworks Solutions, Regeneron Pharmaceuticals and Universal Health Services

Intercept's (ICPT) OCA Under Priority Review in the U.S.

Amicus (FOLD) Signs Agreement to Acquire Scioderm

Applied Genetic Meets Enrolment Milestone in XLRS Study

Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns

Benzinga's Top Downgrades

Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance

Exelixis Up on Swiss Approval of Advanced Melanoma Drug

See More REGN News...

REGN's Top Competitors

REGN $502.98 (1.32%)
Current stock: REGN
AMGN $148.19 (0.50%)
Current stock: AMGN
GILD $101.90 (0.40%)
Current stock: GILD
BIIB $299.35 (2.34%)
Current stock: BIIB